Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
Release Notes Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
PCO
MCID: PLY011
MIFTS: 59

Polycystic Ovary Syndrome (PCO)

Categories: Blood diseases, Endocrine diseases, Metabolic diseases, Rare diseases, Reproductive diseases
Data Licensing
For inquiries, contact:
[email protected]
Genes Variations Tissues Related diseases Publications Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Polycystic Ovary Syndrome

About this section

MalaCards integrated aliases for Polycystic Ovary Syndrome:

Name: Polycystic Ovary Syndrome 11 42 75 53 41 43 14 16 71 33
Polycystic Ovarian Syndrome 19 42 75 14 31
Stein-Leventhal Syndrome 11 42 33
Polycystic Ovaries 11 28 53
Pcos 11 19 42
Sclerocystic Ovary Syndrome 42 33
Polycystic Ovarian Disease 11 42
Sclerocystic Ovaries 42 71
Multicystic Ovaries 11 42
Polycystic Ovary 11 33
Polycystic Ovary Syndrome, Susceptibility to 5
Pcos - [polycystic Ovary Syndrome] 33
Sclerocystic Ovarian Degeneration 42
Cystic Disease of Ovaries 42
Pco - [polycystic Ovary] 33
Cystic Disease of Ovary 42
Stein-Leventhal Synd. 11
Polycystic Ovary Nos 33
Pcod 42
Pco 42

Classifications:

MalaCards categories:
Global: Rare diseases Metabolic diseases
Anatomical: Endocrine diseases Reproductive diseases Blood diseases
See all MalaCards categories (disease lists)
ICD10: 31
ICD11: 33


External Ids:

Disease Ontology 11 DOID:11612
ICD9CM 34 256.4
MeSH 43 D011085
NCIt 49 C26862
SNOMED-CT 68 69878008
ICD10 31 E28.2
UMLS 71 C0032460 C1136382
Sources

Summaries for Polycystic Ovary Syndrome

About this section

MedlinePlus Genetics: 42 Polycystic ovary syndrome is a condition that affects women in their child-bearing years and alters the levels of multiple hormones, resulting in problems affecting many body systems.Most women with polycystic ovary syndrome produce excess male sex hormones (androgens), a condition called hyperandrogenism. Having too much of these hormones typically leads to excessive body hair growth (hirsutism), acne, and male pattern baldness.Hyperandrogenism and abnormal levels of other sex hormones prevent normal release of egg cells from the ovaries (ovulation) and regular menstrual periods, leading to difficulty conceiving a child (subfertility) or a complete inability to conceive (infertility). For those who achieve pregnancy, there is an increased risk of complications and pregnancy loss. Due to irregular and infrequent menstruation and hormone abnormalities, affected women have an increased risk of cancer of the uterine lining (endometrial cancer).In polycystic ovary syndrome, one or both ovaries can contain multiple small, immature ovarian follicles that can appear as cysts on medical imaging. Normally, ovarian follicles contain egg cells, which are released during ovulation. In polycystic ovary syndrome, abnormal hormone levels prevent follicles from growing and maturing to release egg cells. Instead, these immature follicles accumulate in the ovaries. Affected women can have 12 or more of these follicles. The number of these follicles usually decreases with age.About half of all women with polycystic ovary syndrome are overweight or have obesity and are at increased risk of a fatty liver. Additionally, many women with polycystic ovary syndrome have elevated levels of insulin, which is a hormone that helps control blood sugar levels. By age 40, about 10 percent of overweight women with polycystic ovary syndrome develop abnormally high blood sugar levels (type 2 diabetes), and up to 35 percent develop prediabetes (higher-than-normal blood sugar levels that do not reach the cutoff for diabetes). Obesity and increased insulin levels (hyperinsulinemia) further increase the production of androgens in polycystic ovary syndrome.Women with polycystic ovary syndrome are also at increased risk for developing metabolic syndrome, which is a group of conditions that include high blood pressure (hypertension), increased belly fat, high levels of unhealthy fats and low levels of healthy fats in the blood, and high blood sugar levels. About 20 percent of affected adults experience pauses in breathing during sleep (sleep apnea). Women with polycystic ovary syndrome are more likely than women in the general popluation to have mood disorders such as depression.

MalaCards based summary: Polycystic Ovary Syndrome, also known as polycystic ovarian syndrome, is related to prediabetes syndrome and alopecia, androgenetic, 1, and has symptoms including pelvic pain An important gene associated with Polycystic Ovary Syndrome is PCOS1 (Polycystic Ovary Syndrome 1), and among its related pathways/superpathways are Metabolism of steroids and Glucose / Energy Metabolism. The drugs Iron and Prednisolone phosphate have been mentioned in the context of this disorder. Affiliated tissues include ovary, liver and skin, and related phenotypes are Increased shRNA abundance (Z-score > 2) and homeostasis/metabolism

MedlinePlus: 41 Polycystic ovary syndrome (PCOS) happens when a woman's ovaries or adrenal glands produce more male hormones than normal. PCOS causes cysts (fluid-filled sacs) to grow on the ovaries. Symptoms include: Irregular menstrual periods Infertility Pelvic pain Excess hair growth on the face, chest, stomach, or thighs Weight gain Acne or oily skin Patches of thickened skin Women with PCOS are at higher risk of diabetes, metabolic syndrome, heart disease, and high blood pressure. PCOS is more common in women who have obesity or have a mother or sister with PCOS. To diagnose PCOS, your health care provider may do a physical exam, pelvic exam, blood tests, and an ultrasound. There is no cure, but diet, exercise, and medicines can help control the symptoms. Birth control pills help women have normal periods, reduce male hormone levels, and clear acne. Treatments for infertility caused by PCOS may include medicines, surgery, and in vitro fertilization (IVF). NIH: National Institute of Child Health and Human Development

Disease Ontology: 11 An ovarian dysfunction that is characterized by hyperandrogenism, polycystic ovaries, hirsutism, oligomenorrhea or amenorrhea, anovulation and excessive body weight.

Wikipedia: 75 Polycystic ovary syndrome, or PCOS, is the most common endocrine disorder in women of reproductive age.... more...
Sources

Related Diseases for Polycystic Ovary Syndrome

About this section

Diseases in the Polycystic Ovary Syndrome family:

Polycystic Ovary Syndrome 1

Diseases related to Polycystic Ovary Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 859)
# Related Disease Score Top Affiliating Genes
1 prediabetes syndrome 32.7 SHBG LEP INSR INS IGF1 CAPN10
2 alopecia, androgenetic, 1 32.6 SHBG CYP21A2 CYP19A1
3 ovarian cyst 32.5 SHBG PRL GNRH1 CYP19A1 AMH
4 hyperinsulinism 32.4 SHBG LEP INSR INS IGF1 GNRH1
5 cytochrome p450 oxidoreductase deficiency 32.4 CYP21A2 CYP19A1 CYP17A1
6 hyperandrogenism 32.3 SHBG PRL INSR INS IGF1 GNRH1
7 leptin deficiency or dysfunction 32.2 LEP INS IGF1 GNRH1
8 acne 32.2 SHBG PRL LEP INS IGF1 CYP21A2
9 lipid metabolism disorder 32.1 SHBG LEP INSR INS IGF1 CYP21A2
10 type 2 diabetes mellitus 32.1 SHBG PRL LEP INSR INS IGF1
11 glucose intolerance 32.1 SHBG PRL LEP INSR INS IGF1
12 gestational diabetes 32.1 SHBG PRL LEP INSR INS IGF1
13 ovarian disease 32.0 SHBG PRL LEP INSR INS IGF1
14 anovulation 32.0 SHBG PRL LEP INS IGF1 GNRH1
15 ovarian hyperstimulation syndrome 32.0 SHBG INS GNRH1 FSHR CYP19A1 CYP11A1
16 infertility 32.0 SHBG PRL LEP GNRH1 GDF9 FSHR
17 fatty liver disease 32.0 LEP INSR INS IGF1
18 acanthosis nigricans 32.0 SHBG LEP INSR INS IGF1
19 pre-eclampsia 31.9 SHBG LEP INS IGF1 FST
20 alopecia 31.9 SHBG PRL IGF1 CYP19A1
21 hyperprolactinemia 31.8 SHBG PRL INS IGF1 GNRH1
22 apnea, obstructive sleep 31.8 LEP INS IGF1
23 amenorrhea 31.7 SHBG PRL LEP INS IGF1 GNRH1
24 eating disorder 31.7 LEP INS IGF1
25 sleep apnea 31.7 LEP INS IGF1
26 hypothyroidism 31.7 SHBG PRL LEP INS IGF1 GNRH1
27 insulin-like growth factor i 31.6 SHBG PRL LEP INSR INS IGF1
28 androgenic alopecia 31.6 SHBG PRL INS IGF1 CYP19A1
29 diabetes mellitus 31.6 SHBG PRL LEP INSR INS IGF1
30 hyperglycemia 31.5 LEP INSR INS IGF1
31 endometriosis 31.5 GNRH1 FSHR CYP19A1 CYP17A1
32 non-alcoholic fatty liver disease 31.5 MSR1 LEP INSR INS
33 body mass index quantitative trait locus 11 31.4 SHBG PRL LEP INSR INS IGF1
34 sleep disorder 31.4 LEP INS IGF1
35 endometrial cancer 31.3 SHBG LEP INS IGF1 GNRH1 GAS5
36 hypoglycemia 31.3 PRL LEP INSR INS IGF1
37 adult syndrome 31.3 LEP INS IGF1
38 galactorrhea 31.3 PRL IGF1
39 estrogen excess 31.2 SHBG PRL GNRH1 CYP19A1 AMH
40 goiter 31.1 SHBG PRL INS IGF1
41 male infertility 31.1 SHBG GNRH1 FSHR CYP21A2 CYP19A1 AMH
42 conn's syndrome 31.1 PRL LEP INS IGF1 GNRH1 CYP21A2
43 acromegaly 31.1 SHBG PRL LEP INS IGF1 GNRH1
44 sexual health disorder 31.1 SHBG PRL GNRH1
45 lipoid congenital adrenal hyperplasia 31.0 SHBG PRL LEP INS IGF1 GNRH1
46 central precocious puberty 31.0 LEP IGF1 GNRH1 AMH
47 hypogonadism 31.0 SHBG PRL LEP INS IGF1 GNRH1
48 pituitary gland disease 31.0 PRL INS IGF1 GNRH1
49 endogenous depression 31.0 PRL INS GNRH1
50 endometrial disease 30.9 IGF1 GNRH1 AMH

Graphical network of the top 20 diseases related to Polycystic Ovary Syndrome:



Diseases related to Polycystic Ovary Syndrome
Sources

Symptoms & Phenotypes for Polycystic Ovary Syndrome

About this section

UMLS symptoms related to Polycystic Ovary Syndrome:


pelvic pain

GenomeRNAi Phenotypes related to Polycystic Ovary Syndrome according to GeneCards Suite gene sharing:

25 (show all 40)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-100 9.97 CYP21A2
2 Increased shRNA abundance (Z-score > 2) GR00366-A-104 9.97 LEP
3 Increased shRNA abundance (Z-score > 2) GR00366-A-105 9.97 CYP21A2
4 Increased shRNA abundance (Z-score > 2) GR00366-A-112 9.97 LEP
5 Increased shRNA abundance (Z-score > 2) GR00366-A-113 9.97 LEP
6 Increased shRNA abundance (Z-score > 2) GR00366-A-114 9.97 IGF1
7 Increased shRNA abundance (Z-score > 2) GR00366-A-127 9.97 LEP
8 Increased shRNA abundance (Z-score > 2) GR00366-A-138 9.97 IGF1
9 Increased shRNA abundance (Z-score > 2) GR00366-A-139 9.97 CYP21A2 IGF1
10 Increased shRNA abundance (Z-score > 2) GR00366-A-142 9.97 INSR
11 Increased shRNA abundance (Z-score > 2) GR00366-A-145 9.97 CYP21A2
12 Increased shRNA abundance (Z-score > 2) GR00366-A-161 9.97 CYP21A2 IGF1
13 Increased shRNA abundance (Z-score > 2) GR00366-A-163 9.97 IGF1
14 Increased shRNA abundance (Z-score > 2) GR00366-A-164 9.97 IGF1
15 Increased shRNA abundance (Z-score > 2) GR00366-A-169 9.97 SHBG
16 Increased shRNA abundance (Z-score > 2) GR00366-A-176 9.97 IGF1
17 Increased shRNA abundance (Z-score > 2) GR00366-A-18 9.97 INSR
18 Increased shRNA abundance (Z-score > 2) GR00366-A-184 9.97 CYP21A2
19 Increased shRNA abundance (Z-score > 2) GR00366-A-185 9.97 CYP21A2
20 Increased shRNA abundance (Z-score > 2) GR00366-A-191 9.97 SHBG
21 Increased shRNA abundance (Z-score > 2) GR00366-A-193 9.97 IGF1
22 Increased shRNA abundance (Z-score > 2) GR00366-A-196 9.97 INSR
23 Increased shRNA abundance (Z-score > 2) GR00366-A-199 9.97 LEP
24 Increased shRNA abundance (Z-score > 2) GR00366-A-203 9.97 CYP21A2
25 Increased shRNA abundance (Z-score > 2) GR00366-A-206 9.97 CYP21A2
26 Increased shRNA abundance (Z-score > 2) GR00366-A-207 9.97 SHBG
27 Increased shRNA abundance (Z-score > 2) GR00366-A-208 9.97 CYP21A2 IGF1
28 Increased shRNA abundance (Z-score > 2) GR00366-A-213 9.97 CYP21A2 LEP
29 Increased shRNA abundance (Z-score > 2) GR00366-A-216 9.97 LEP
30 Increased shRNA abundance (Z-score > 2) GR00366-A-29 9.97 IGF1
31 Increased shRNA abundance (Z-score > 2) GR00366-A-40 9.97 INSR
32 Increased shRNA abundance (Z-score > 2) GR00366-A-42 9.97 INSR
33 Increased shRNA abundance (Z-score > 2) GR00366-A-45 9.97 SHBG
34 Increased shRNA abundance (Z-score > 2) GR00366-A-46 9.97 SHBG
35 Increased shRNA abundance (Z-score > 2) GR00366-A-55 9.97 LEP
36 Increased shRNA abundance (Z-score > 2) GR00366-A-60 9.97 INSR
37 Increased shRNA abundance (Z-score > 2) GR00366-A-63 9.97 CYP21A2
38 Increased shRNA abundance (Z-score > 2) GR00366-A-8 9.97 CYP21A2
39 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.97 INSR
40 Increased shRNA abundance (Z-score > 2) GR00366-A-99 9.97 IGF1

MGI Mouse Phenotypes related to Polycystic Ovary Syndrome:

45 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.34 AMH CAPN10 CYP11A1 CYP17A1 CYP19A1 FSHR
2 nervous system MP:0003631 10.24 CYP11A1 CYP19A1 FSHR FST GNRH1 IGF1
3 growth/size/body region MP:0005378 10.22 AMH CAPN10 CYP11A1 CYP17A1 CYP19A1 CYP21A2
4 endocrine/exocrine gland MP:0005379 10.18 AMH CAPN10 CYP11A1 CYP19A1 FSHR FST
5 liver/biliary system MP:0005370 10.08 CAPN10 CYP11A1 CYP19A1 GNRH1 INS INSR
6 adipose tissue MP:0005375 10.06 CAPN10 CYP17A1 CYP19A1 FSHR IGF1 INS
7 cardiovascular system MP:0005385 10.06 CAPN10 CYP11A1 CYP17A1 CYP19A1 FSHR FST
8 immune system MP:0005387 10.03 CAPN10 CYP11A1 CYP19A1 CYP21A2 FSHR GNRH1
9 reproductive system MP:0005389 9.97 AMH CYP11A1 CYP17A1 CYP19A1 FSHR FST
10 skeleton MP:0005390 9.7 CAPN10 CYP11A1 CYP17A1 CYP19A1 FSHR FST
11 integument MP:0010771 9.28 CYP19A1 CYP21A2 FSHR FST GNRH1 IGF1
Sources

Drugs & Therapeutics for Polycystic Ovary Syndrome

About this section

Drugs for Polycystic Ovary Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 317)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Iron Approved Phase 4 7439-89-6 29936
2
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
3
Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
4
Prednisolone Approved, Vet_approved Phase 4 50-24-8 4894 5755
5
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5 1875
6
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 4159 6741
7
Cyproterone acetate Approved, Investigational Phase 4 427-51-0 9880
8
Simvastatin Approved Phase 4 79902-63-9 54454
9
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
10
Mecobalamin Approved, Investigational Phase 4 13422-55-4
11
Hydroxocobalamin Approved Phase 4 13422-51-0 15589840 44475014
12
Canagliflozin Approved Phase 4 842133-18-0 74323022 24812758
13
Acetylcysteine Approved, Investigational Phase 4 616-91-1 581 12035
14
Citalopram Approved Phase 4 59729-32-7, 59729-33-8 2771
15
Liraglutide Approved Phase 4 204656-20-2 44147092 16134956
16
Glucagon Approved Phase 4 16941-32-5 16133228 16186314
17
Dulaglutide Approved, Investigational Phase 4 923950-08-7
18
Tamoxifen Approved Phase 4 10540-29-1, 54965-24-1 2733526
19
Acarbose Approved, Investigational Phase 4 56180-94-0 441184 444254
20
Leuprolide Approved, Investigational Phase 4 53714-56-0 657181
21
Rosiglitazone Approved, Investigational Phase 4 122320-73-4, 155141-29-0 77999
22
Moxonidine Approved, Investigational Phase 4 75438-57-2 4810
23
Sibutramine Approved, Illicit, Investigational, Withdrawn Phase 4 106650-56-0 5210
24
Alogliptin Approved Phase 4 850649-61-5 11450633
25
Ketamine Approved, Vet_approved Phase 4 6740-88-1, 1867-66-9 3821
26
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
27
Ethinylestradiol Approved Phase 4 57-63-6 5991
28
Drospirenone Approved Phase 4 67392-87-4 68873
29
Cetrorelix Approved, Investigational Phase 4 120287-85-6 25074887
30
Empagliflozin Approved Phase 4 864070-44-0 73151030 11949646
31
Magnesium sulfate Approved, Investigational, Vet_approved Phase 4 7487-88-9
32
Linagliptin Approved Phase 4 668270-12-0 57389748 10096344
33
Etonogestrel Approved, Investigational Phase 4 54048-10-1 6917715
34
Artenimol Approved, Experimental, Investigational Phase 4 71939-50-9 540327
35
Dydrogesterone Approved, Investigational, Withdrawn Phase 4 152-62-5 9051
36
Lactitol Approved, Investigational Phase 4 585-86-4 157355
37
Testosterone Approved, Investigational Phase 4 58-22-0 5408 6013
38
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
39
Levoleucovorin Approved, Experimental, Investigational Phase 4 68538-85-2, 58-05-9, 73951-54-9 149436 6006
40
Ubidecarenone Approved, Investigational, Nutraceutical Phase 4 303-98-0 5281915
41
Cyanocobalamin Approved, Nutraceutical Phase 4 68-19-9 24892734 16212801 44176380
42
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 4 65-23-6 1054
43
Calcifediol Approved, Nutraceutical Phase 4 19356-17-3 5283731
44
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
45
Isotretinoin Approved, Investigational, Nutraceutical Phase 4 302-79-4, 4759-48-2 5538 444795 5282379
46
Manganese Approved, Nutraceutical Phase 4 7439-96-5 27854
47
Cysteine Approved, Nutraceutical Phase 4 52-90-4 594 5862
48
Lipoic acid Approved, Investigational, Nutraceutical Phase 4 1200-22-2 864 6112
49
Cholecalciferol Approved, Nutraceutical, Vet_approved Phase 4 67-97-0, 1406-16-2 5280795 10883523
50
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7 4897

Interventional clinical trials:

(show top 50) (show all 782)
# Name Status NCT ID Phase Drugs
1 Prospective, Randomized, Double - Blind, Placebo Controlled Trial of Dietary Modification in Conjunction With Probiotic Therapy on Clinical and Endocrinological Parameters as Well as Body Composition in Women With Polycystic Ovary Syndrome Unknown status NCT03325023 Phase 4
2 Prospective, Randomized, Double - Blind Placebo Controlled Trial of Simvastatin and Resveratrol Therapy on Clinical, Endocrinological, Biochemical and Endothelial Dysfunction Parameters in Women With Polycystic Ovary Syndrome. Unknown status NCT02766803 Phase 4 Simvastatin and micronized trans-resveratrol
3 Comparison of Three Different Strategies for Treating Infertility in Anovulatory Women With Polycystic Ovary Syndrome: a Multicentre Randomized Controlled Clinical Trial Unknown status NCT00461643 Phase 4 Clomiphene citrate, metformin, metformin plus clomiphene citrate, gonadotropins
4 Treatment of Obesity With Topiramate in Patients With Polycystic Ovary Syndrome: a Double-blind Placebo-controlled Clinical Trial Unknown status NCT04453306 Phase 4 Topiramate;Placebo
5 Study on the Effect of Metformin vs Metformin Combined With GLP-1 RA (Exenatide) on Overweight/Obese Patients With Polycystic Ovary Syndrome (PCOS) Unknown status NCT04029272 Phase 4 Metformin;Exenatide 2 MG
6 Research of Intensive Metabolic Intervention Before Pregnancy in Polycystic Ovary Syndrome Unknown status NCT03383068 Phase 4 Acarbose 100 MG;Exenatide;Orlistat;Metformin
7 Pulsatile Gonadotropin-releasing Hormone for Infertility in Non-obese Patients With Polycystic Ovary Syndrome Unknown status NCT03989024 Phase 4 Gonadorelin;Clomiphene
8 The Effects of Contraceptive Pill and Hormonal Vaginal Ring on Hormonal, Inflammatory and Metabolic Parameters in Women of Reproductive Age With Polycystic Ovary Syndrome (PCOS). Unknown status NCT01588873 Phase 4 oc:E-E-desogestrel/vaginal ring:E-E -ethonogestrel
9 Therapeutic Monitoring of Metformin in Women With Polycystic Ovary Syndrome Unknown status NCT01366391 Phase 4 Metformin
10 The Effect of Diane-35 Pretreatment on Endocrine and Clinical Profile for Patients With Polycystic Ovary Syndrome Undergoing In-vitro Fertilization Unknown status NCT01752270 Phase 4 Diane-35 pretreatment
11 The Effect of Weight Loss With Orlistat or Sibutramine Administration , Hypocaloric Diet and Physical Exercise , on AMH Levels, in Women With Polycystic Ovary Syndrome Unknown status NCT01475019 Phase 4 Orlistat;Sibutramine
12 Effects of Different Therapies on Surrogate Markers of Cardiovascular Risk in Women With Polycystic Ovary Syndrome (PCOS) Unknown status NCT01798875 Phase 4 oral metformin;oral contraceptive
13 A Comparison Study of a Novel Stimulation Protocol With Metformin in Step-down Regimen and the Conventional Low Dose Step-up Protocol in Patients With Polycystic Ovary Syndrome Undergoing in Vitro Fertilization Unknown status NCT01438190 Phase 4 Metformin, gonadotropins in step-down regimen;Placebo, gonadotropins in step-up regimen
14 Efficacy of Long- Versus Short-term Metformin Protocol in Infertile Anovulatory PCOS Patients Unknown status NCT00501904 Phase 4 Metformin
15 CLASSICAL ANTAGONIST PROTOCOL IN COMPARISON WITH AGONIST STOP PROTOCOL IN Polycystic Ovary Symdrome WOMEN UNDERGOING Intra-cytoplasmic Injection TRIAL: a Randomized Controlled Trial Unknown status NCT04094467 Phase 4 Cetrorelix;Leuprolide Acetate
16 Randomized Controlled Trial Comparing the Effect of GnRH Agonist and Antagonist Ovarian Stimulation Protocols in PCOS Patients Unknown status NCT00417144 Phase 4 Arvekap 0.1mg (Triptorelin, Ipsen, France);Ganirelix 0.25mg (Orgalutran, Organon, The Netherlands)
17 The Effect Of Vitamin D Replacement Therapy On Serum Leptin And Follicular Growth Pattern In Women With Resistant Polycystic Ovarian Syndrome Unknown status NCT03806036 Phase 4 Vitamin D;Clomiphene Citrate
18 Myo-inositol Versus Clomiphene Citrate as First Line Treatment for Ovulation Induction in PCOS Unknown status NCT04306692 Phase 4 Myo-inositol;Clomiphene Citrate
19 PERCING : Ovarian Drilling Versus Ovarian Stimulation + Intra Uterine Insemination (IUI) + Metformin in the PCOS (PolyCystic Ovaries Syndrome) Treatment Unknown status NCT00378729 Phase 4 Metformin and FSHr
20 Metformin Treatment for Preventing Gestational Diabetes in High-risk Patients Unknown status NCT00883259 Phase 4 Metformin
21 Randomized Clinical Trial to Evaluate The Effect of Metformin-GLP-1 Receptor Agonist Versus Oral Contraceptive (OC) Therapy on Reproductive Disorders and Cardiovascular Risks in Overweight Polycystic Ovarian Syndrome (PCOS) Patients Unknown status NCT03151005 Phase 4 Metformin-GLP-1 Receptor Agonist;Metformin-Oral Contraceptive(OC)
22 Endometrial Thickness And Subendometrial Vascularity In Anovulatory Polycystic Ovarian Syndrome Patients Treated by Metformin Unknown status NCT03486626 Phase 4 Metformin
23 Endometrial Scratching at Time of Laproscopic Ovarian Drilling in Women With Anovulatory Infertility Due to Polycystic Ovarian Syndrome (PCOS): Randomized Controlled Trial. Unknown status NCT02140398 Phase 4
24 The Changes of Hemocoagulation and Lipoperoxidation in Women Using Combined Oral Contraceptives With Antiandrogenic Activity, Correction by Antioxidants Unknown status NCT02027337 Phase 4 20 mcg ethinylestradiol /3 mg drospirenone;20 mcg ethinylestradiol/3 mg drospirenone and Selmevit;30 mcg ethinylestradiol/3 mg drospirenone;30 mcg ethinylestradiol/3 mg drospirenone and Selmevit;35 mcg ethinylestradiol/2 mg cyproterone;35 mcg ethinylestradiol/2 mg cyproterone and Selmevit
25 Adding Prednisolone During Ovulation Induction With Clomiphene Citrate in Lean Women With Clomiphene Citrate Resistant Polycystic Ovarian Syndrome Unknown status NCT02344888 Phase 4 Clomiphene citrate and Prednisolone;Clomiphene citrate and folic acid
26 Use of Low Dose of Human Chorionic Gonadotropin During Ovulation Induction With Clomiphene Citrate in Women With Clomiphene Citrate Resistant Polycystic Ovarian Syndrome Unknown status NCT02436226 Phase 4 Clomiphene citrate and Human chorionic gonadotropin (HCG);Clomiphene citrate
27 Hormone Replacement Therapy Versus Minimal Ovarian Stimulation for Endometrial Preparation Prior to Frozen-thawed Embryo Transfer in Non Polycystic Ovarian Syndrome Patients Unknown status NCT02330757 Phase 4 Estradiol valerate;Sequential Clomiphene citrate and Gonadotropin
28 Corifollitropin Alfa in Combination With Elective Cryopreservation of All Embryos After GnRH Agonist Triggering of Final Oocyte Maturation in PCOS Patients- a Prospective, Observational Proof-of -Concept Study Unknown status NCT02215135 Phase 4 Corifollitropin alfa
29 Combined Letrozole and Clomid in Polycystic Ovary Syndrome: a Randomized Control Trial of Combination of Letrozole and Clomiphene Citrate or Letrozole Alone for the Treatment of Infertility in Women With Polycystic Ovary Syndrome Completed NCT02802865 Phase 4 Clomiphene;Letrozole
30 Randomized, Cross-over Trial With Metformin in Women With Polycystic Ovary Syndrome Completed NCT02280057 Phase 4 Metformin;Placebo
31 Combined Treatment With PDE-4 Inhibitor Roflumilast and Metformin Leads to Significant Weight Loss in Obese Women With Polycystic Ovary Syndrome Completed NCT02037672 Phase 4 metformin;metformin and roflumilast
32 Effects of Structured Exercise Program Versus Hypocaloric Hyperproteic Diet on the Reproductive Function in Obese Anovulatory Infertile Patients With Polycystic Ovary Syndrome: a 24-Week Prospective Study. Completed NCT00473538 Phase 4
33 Insulin Sensitivity After Metformin Suspension in Normal-Weight Women With Polycystic Ovary Syndrome Completed NCT00437333 Phase 4 Metformin cloridrate
34 The Cardiovascular Risk Profile Associated With The Polycystic Ovary Syndrome And With Ovulatory Hyperandrogenism, And Its Changes During Treatment With Metformin Or Oral Contraceptives Completed NCT00428311 Phase 4 Metformin;Ethynyl-estradiol plus cyproterone acetate
35 Inkretineffekten Hos Patienter Med Polycystisk Ovariesyndrom før og Efter Behandling af Insulinresistens (Incretin Effect in Patients With Polycystic Ovary Syndrome Before and After Treatment of Insulin Resistance) Completed NCT01892254 Phase 4 Metformin;Placebo
36 Multi-Centre Randomised Controlled Trial of the Effectiveness of Metformin and Clomiphene Citrate for Treating Anovulatory Infertility in Women With Polycystic Ovary Syndrome Completed NCT00795808 Phase 4 Metformin;Placebo;Metformin + Clomiphene;Clomiphene
37 Laparoscopic Ovarian Diathermy or Metformin Plus Clomiphene Citrate Administration as Second-Line Treatment for Infertile Anovulatory Patients With Polycystic Ovary Syndrome: a Randomized Controlled Trial Completed NCT00558077 Phase 4 Metformin plus clomiphene citrate
38 Dose Vitamin-D Supplementation Affect Reproductive Outcomes in Patients With Polycystic Ovary Syndrome? Completed NCT03898934 Phase 4 Vitamin D;Placebo Oral Tablet
39 The Efficacy of Canagliflozin Versus Metformin in Women With Polycystic Ovary Syndrome: A Randomized, Open Label Trial Completed NCT04700839 Phase 4 SGLT2 inhibitors;Metformin
40 Clomiphene Citrate Versus Metformin as First-Line Approach for the Treatment of Anovulation in Infertile Patients With Polycystic Ovary Syndrome Completed NCT00471523 Phase 4 Clomiphene citrate;Metformin
41 The Effect of Cipralex in Polycystic Ovary Syndrome Completed NCT01961180 Phase 4 Cipralex;Placebo
42 Short-term Combined Treatment With Liraglutide and Metformin Leads to Significant Weight Loss in Obese Women With Polycystic Ovary Syndrome and Previous Poor Response to Metformin Completed NCT01911468 Phase 4 metformin;liraglutide;metformin and liraglutide
43 Clinical Metabolic and Endocrine Parameters in Response to Metformin and Lifestyle Intervention in Women With Polycystic Ovary Syndrome: A Phase 4 Randomized, Double- Blind and Placebo Control Trial Completed NCT00679679 Phase 4 Metformin;Placebo
44 Combined Coenzyme Q10 and Clomiphene Citrate for Ovulation Induction in Clomiphene-citrate-resistant Polycystic Ovary Syndrome Completed NCT04302532 Phase 4 Coenzyme Q10;clomiphene citrate
45 Short-term Liraglutide Treatment in Obese Women With Polycystic Ovary Syndrome Completed NCT01899430 Phase 4 liraglutide;metformin
46 Clomiphene Citrate Plus N-acetyl Cysteine Versus Clomiphene Citrate for Induction of Ovulation in Women With Newly Diagnosed Polycystic Ovary Syndrome: a Randomized Double-blind Controlled Trial Completed NCT01896492 Phase 4 NAC
47 A Randomised, Double-blind, Placebo-controlled Study of the Effect of Liraglutide in Polycystic Ovary Syndrome on Risk Markers of Vascular Thrombosis. Completed NCT02073929 Phase 4 Liraglutide for 26 weeks;placebo
48 Effects of Metformin With or Without Folate Supplementation on Homocysteine Levels and Endothelium in Women With Polycystic Ovary Syndrome Completed NCT00953355 Phase 4 Folate plus metformin;Placebo plus metformin
49 Dipeptidyl Peptidase-4 (DPP-4) Inhibitor Sitagliptin Improved Beta Cell Function and Prevented a Conversion Rate to Impaired Glucose Tolerance IGT and Type 2 Diabetes T2D in Metformin Intolerant Obese Women With Polycystic Ovary Syndrome PCOS Completed NCT03122041 Phase 4 Sitagliptin
50 Liraglutide as Add on Therapy on Metformin in Women With Polycystic Ovary Syndrome Completed NCT02483299 Phase 4 Metformin;Glucophage tablets and Victoza

Search NIH Clinical Center for Polycystic Ovary Syndrome

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Urofollitropin

Cochrane evidence based reviews: polycystic ovary syndrome

Sources

Genetic Tests for Polycystic Ovary Syndrome

About this section

Genetic tests related to Polycystic Ovary Syndrome:

# Genetic test Affiliating Genes
1 Polycystic Ovaries 28
Sources

Anatomical Context for Polycystic Ovary Syndrome

About this section

Organs/tissues related to Polycystic Ovary Syndrome:

MalaCards : Ovary, Liver, Skin, Heart, Endothelial, Skeletal Muscle, Pituitary
Sources

Publications for Polycystic Ovary Syndrome

About this section

Articles related to Polycystic Ovary Syndrome:

(show top 50) (show all 21693)
# Title Authors PMID Year
1
Specific CAPN10 gene haplotypes influence the clinical profile of polycystic ovary patients. 53 62 5
14602801 2003
2
Comment: CAPN10 alleles are associated with polycystic ovary syndrome. 53 62 5
12161543 2002
3
Circulating Anti-Müllerian hormone in a cohort-study of women with severe obesity with and without polycystic ovary syndrome and the effect of a one-year weight loss intervention. 62 41
36309748 2022
4
Canagliflozin combined with metformin versus metformin monotherapy for endocrine and metabolic profiles in overweight and obese women with polycystic ovary syndrome: A single-center, open-labeled prospective randomized controlled trial. 62 41
36147577 2022
5
Cangfudaotan decoction inhibits mitochondria-dependent apoptosis of granulosa cells in rats with polycystic ovarian syndrome. 62 41
36465612 2022
6
Meta-analysis and a large association study confirm a role for calpain-10 variation in type 2 diabetes susceptibility. 5
14574648 2003
7
Studies of association between the gene for calpain-10 and type 2 diabetes mellitus in the United Kingdom. 5
11481585 2001
8
Genetic variation in the gene encoding calpain-10 is associated with type 2 diabetes mellitus. 5
11017071 2000
9
Genetic variations of follicle stimulating hormone receptor are associated with polycystic ovary syndrome. 53 62
20514429 2010
10
CYP19 gene: a genetic modifier of polycystic ovary syndrome phenotype. 53 62
19324338 2010
11
Expression of growth differentiation factor-9 and bone morphogenetic protein-15 in oocytes and cumulus granulosa cells of patients with polycystic ovary syndrome. 53 62
19376510 2010
12
No association of the G972S polymorphism of the insulin receptor substrate-1 gene with polycystic ovary syndrome in lean PCOS women with biochemical hyperandrogenemia. 53 62
20012307 2010
13
C-reactive protein and homocysteine levels are associated with abnormal heart rate recovery in women with polycystic ovary syndrome. 53 62
19362308 2010
14
FSH receptor, KL1/2, P450, and PAPP genes in granulosa-lutein cells from in vitro fertilization patients show a different expression pattern depending on the infertility diagnosis. 53 62
19342032 2010
15
Insulin resistance and overweight-obese women with polycystic ovary syndrome. 53 62
19903118 2010
16
Identification of the G994T polymorphism in exon 9 of plasma platelet-activating factor acetylhydrolase gene as a risk factor for polycystic ovary syndrome. 53 62
20185515 2010
17
Decreased active, total and altered active to total ghrelin ratio in normal weight women with the more severe form of polycystic ovary syndrome. 53 62
20096985 2010
18
Serum soluble glycoprotein 130 concentration is inversely related to insulin sensitivity in women with polycystic ovary syndrome. 53 62
20103703 2010
19
The effect of serum and intrafollicular insulin resistance parameters and homocysteine levels of nonobese, nonhyperandrogenemic polycystic ovary syndrome patients on in vitro fertilization outcome. 53 62
19171332 2010
20
High-molecular-weight adiponectin is selectively reduced in women with polycystic ovary syndrome independent of body mass index and severity of insulin resistance. 53 62
20080859 2010
21
Serum resistin and adiponectin levels in young non-obese women with polycystic ovary syndrome. 53 62
20148738 2010
22
Hepatic steatosis in young lean insulin resistant women with polycystic ovary syndrome. 53 62
19171337 2010
23
Effect of rimonabant and metformin on glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 in obese women with polycystic ovary syndrome. 53 62
19489873 2010
24
Increased follistatin levels after oral contraceptive treatment in obese and non-obese women with polycystic ovary syndrome. 53 62
20093255 2010
25
[Polymorphism of CYP11A1 gene in Chinese patients with polycystic ovarian syndrome]. 53 62
20450755 2010
26
Flexible GnRH antagonist protocol versus GnRH agonist long protocol in patients with polycystic ovary syndrome treated for IVF: a prospective randomised controlled trial (RCT). 53 62
20008886 2010
27
Serum retinol-binding protein 4 levels in nonobese women with polycystic ovary syndrome. 53 62
19028383 2010
28
Polymorphisms of the insulin receptor and the insulin receptor substrates genes in polycystic ovary syndrome: a Mendelian randomization meta-analysis. 53 62
19926323 2010
29
Decreased adiponectin levels in polycystic ovary syndrome, independent of body mass index. 53 62
19929617 2010
30
Effect of metformin on serum visfatin levels in patients with polycystic ovary syndrome. 53 62
19111298 2010
31
Regulation of adiponectin secretion by adipocytes in the polycystic ovary syndrome: role of tumor necrosis factor-{alpha}. 53 62
20089616 2010
32
Metformin versus laparoscopic ovarian drilling in clomiphene- and insulin-resistant women with polycystic ovary syndrome. 53 62
19892338 2010
33
Endothelial function and insulin resistance in polycystic ovary syndrome: the effects of medical therapy. 53 62
19019358 2010
34
Association of insulin resistance with anti-Mullerian hormone levels in women without polycystic ovary syndrome (PCOS). 53 62
19438903 2010
35
[Activity and distribution of plasma platelet-activating factor acetylhydrolase in polycystic ovary syndrome patients with insulin resistance]. 53 62
20367923 2010
36
Adiponectin and resistin concentrations after glucose load in adolescents with polycystic ovary syndrome. 53 62
19639497 2010
37
Unilateral ovarian enlargement in adolescents with polycystic ovary syndrome: a variant of bilateral disease. 53 62
20432811 2010
38
Adiponectin levels reflect the different phenotypes of polycystic ovary syndrome: study in normal weight, normoinsulinemic patients. 53 62
19700156 2009
39
Altered distribution of plasma platelet-activating factor acetylhydrolase between high-density lipoprotein and low-density lipoprotein in patients with polycystic ovary syndrome. 53 62
19596311 2009
40
The relationship between follistatin and chronic low-grade inflammation in women with polycystic ovary syndrome. 53 62
19591997 2009
41
Central-to-peripheral fat ratio, but not peripheral body fat, is related to insulin resistance and androgen markers in polycystic ovary syndrome. 53 62
19905998 2009
42
[Increased risk of early pregnancy loss and lower live birth rate with GNRH antagonist vs. long GNRH agonist protocol in PCOS women undergoing controlled ovarian hyperstimulation]. 53 62
20209851 2009
43
Association between CYP19 gene SNP rs2414096 polymorphism and polycystic ovary syndrome in Chinese women. 53 62
20015405 2009
44
Adiponectin levels in adolescent girls with polycystic ovary syndrome (PCOS). 53 62
19389110 2009
45
Response of IGF and IL-6 to ovarian stimulation in PCOS and normal women. 53 62
19938957 2009
46
Effects of polymorphisms of the sex hormone-binding globulin (SHBG) gene on free estradiol and bone mineral density. 53 62
19679209 2009
47
[The activity of platelet activating factor acetylhydrolase and its metabolic profile in patients with polycystic ovary syndrome]. 53 62
20067121 2009
48
Body fat and insulin resistance independently predict increased serum C-reactive protein in hyperandrogenic women with polycystic ovary syndrome. 53 62
19713424 2009
49
Thyroid-stimulating hormone is associated with insulin resistance independently of body mass index and age in women with polycystic ovary syndrome. 53 62
19654109 2009
50
Association of single nucleotide polymorphisms in adiponectin and its receptor genes with polycystic ovary syndrome. 53 62
20120899 2009
Sources

Variations for Polycystic Ovary Syndrome

About this section

ClinVar genetic disease variations for Polycystic Ovary Syndrome:

5
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 CAPN10 NM_023083.4(CAPN10):c.471-187T>C SNV Risk Factor
 5096 rs2975760 GRCh37: 2:241531163-241531163
GRCh38: 2:240591746-240591746
Sources

Expression for Polycystic Ovary Syndrome

About this section
Search GEO for disease gene expression data for Polycystic Ovary Syndrome.
Sources

Pathways for Polycystic Ovary Syndrome

About this section

Pathways related to Polycystic Ovary Syndrome according to GeneCards Suite gene sharing:

(show all 17)
# Super pathways Score Top Affiliating Genes
1
Metabolism of steroids 66
Show member pathways
 12.42 INS CYP21A2 CYP19A1 CYP17A1 CYP11A1
2
Glucose / Energy Metabolism 3
12.29 INSR INS CYP19A1 CYP17A1 CYP11A1
3
Mesenchymal Stem Cells and Lineage-specific Markers 65
11.69 LEP INS IGF1
4
Metabolism of steroid hormones 66
Show member pathways
 11.61 CYP21A2 CYP19A1 CYP17A1 CYP11A1
5
G-protein signaling_RhoA regulation pathway 22
11.54 INSR IGF1 GNRH1 GDF9
6
Pluripotent stem cell differentiation pathway 74
11.35 INS IGF1 FST
7
Nonalcoholic fatty liver disease 74
11.32 LEP INSR INS
8
Ovarian infertility 74
11.17 CYP19A1 FSHR GDF9
9
Signaling events mediated by PTP1B 61
11.12 PRL LEP INSR INS
10
Leptin-insulin signaling overlap 74
Show member pathways
 10.99 LEP INSR INS
11
Insulin-mediated glucose transport 61
10.85 INSR INS
12
Kisspeptin/kisspeptin receptor system in the ovary 74
10.84 GDF9 FSHR CYP11A1 AMH
13
Nongenotropic Androgen signaling 61
10.81 SHBG GNRH1
14
Antipsychotics Pathway (Metabolic Side Effects), Pharmacodynamics 60
10.73 PRL LEP INS
15
Hormone ligand-binding receptors 66
10.6 GNRH1 FSHR
16
Alternative pathway of fetal androgen synthesis 74
10.55 CYP17A1 CYP11A1
17
Metabolic disorders of biological oxidation enzymes 66
10.46 CYP21A2 CYP19A1 CYP17A1 CYP11A1
Sources

GO Terms for Polycystic Ovary Syndrome

About this section

Biological processes related to Polycystic Ovary Syndrome according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell population proliferation GO:0008284 10.29 PRL LEP INSR INS IGF1 GDF9
2 positive regulation of MAPK cascade GO:0043410 10.16 LEP INSR INS IGF1
3 positive regulation of protein kinase B signaling GO:0051897 10.11 LEP INSR INS IGF1
4 positive regulation of mitotic nuclear division GO:0045840 9.95 INSR INS IGF1
5 activation of protein kinase B activity GO:0032148 9.93 INSR INS IGF1
6 female gonad development GO:0008585 9.91 CYP19A1 FSHR FST
7 sterol metabolic process GO:0016125 9.88 CYP21A2 CYP19A1 CYP11A1
8 regulation of protein phosphorylation GO:0001932 9.87 LEP IGF1 FSHR
9 positive regulation of glycolytic process GO:0045821 9.85 INSR INS IGF1
10 positive regulation of respiratory burst GO:0060267 9.84 INSR INS
11 bone mineralization involved in bone maturation GO:0035630 9.83 IGF1 LEP
12 positive regulation of developmental growth GO:0048639 9.8 LEP INSR
13 positive regulation of glycogen biosynthetic process GO:0045725 9.8 INSR INS IGF1
14 steroid biosynthetic process GO:0006694 9.8 CYP11A1 CYP17A1 CYP19A1 CYP21A2
15 positive regulation of glucose import GO:0046326 9.76 INSR INS IGF1 CAPN10
16 glucocorticoid biosynthetic process GO:0006704 9.43 CYP21A2 CYP17A1 CYP11A1
17 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.32 LEP INSR INS IGF1 FSHR

Molecular functions related to Polycystic Ovary Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 heme binding GO:0020037 9.97 CYP21A2 CYP19A1 CYP17A1 CYP11A1
2 iron ion binding GO:0005506 9.92 CYP21A2 CYP19A1 CYP17A1 CYP11A1
3 insulin-like growth factor receptor binding GO:0005159 9.63 IGF1 INS INSR
4 monooxygenase activity GO:0004497 9.56 CYP21A2 CYP19A1 CYP17A1 CYP11A1
5 hormone activity GO:0005179 9.4 PRL LEP INS IGF1 GNRH1 AMH
6 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen GO:0016705 9.26 CYP21A2 CYP19A1 CYP17A1 CYP11A1
Sources

Sources for Polycystic Ovary Syndrome

About this section
2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....